ID   WEE1_HUMAN              Reviewed;         646 AA.
AC   P30291; B3KVE1; D3DQV0;
DT   01-APR-1993, integrated into UniProtKB/Swiss-Prot.
DT   01-FEB-1996, sequence version 2.
DT   12-OCT-2022, entry version 219.
DE   RecName: Full=Wee1-like protein kinase;
DE            Short=WEE1hu;
DE            EC=2.7.10.2;
DE   AltName: Full=Wee1A kinase;
GN   Name=WEE1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND CHARACTERIZATION.
RX   PubMed=7743995; DOI=10.1002/j.1460-2075.1995.tb07180.x;
RA   Watanabe N., Broome M., Hunter T.;
RT   "Regulation of the human WEE1Hu CDK tyrosine 15-kinase during the cell
RT   cycle.";
RL   EMBO J. 14:1878-1891(1995).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RC   TISSUE=Blood;
RX   PubMed=11528126; DOI=10.1159/000056998;
RA   Cichutek A., Brueckmann T., Seipel B., Hauser H., Schlaubitz S.,
RA   Prawitt D., Hankeln T., Schmidt E.R., Winterpacht A., Zabel B.U.;
RT   "Comparative architectural aspects of regions of conserved synteny on human
RT   chromosome 11p15.3 and mouse chromosome 7 (including genes WEE1 and
RT   LMO1).";
RL   Cytogenet. Cell Genet. 93:277-283(2001).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Amygdala;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16554811; DOI=10.1038/nature04632;
RA   Taylor T.D., Noguchi H., Totoki Y., Toyoda A., Kuroki Y., Dewar K.,
RA   Lloyd C., Itoh T., Takeda T., Kim D.-W., She X., Barlow K.F., Bloom T.,
RA   Bruford E., Chang J.L., Cuomo C.A., Eichler E., FitzGerald M.G.,
RA   Jaffe D.B., LaButti K., Nicol R., Park H.-S., Seaman C., Sougnez C.,
RA   Yang X., Zimmer A.R., Zody M.C., Birren B.W., Nusbaum C., Fujiyama A.,
RA   Hattori M., Rogers J., Lander E.S., Sakaki Y.;
RT   "Human chromosome 11 DNA sequence and analysis including novel gene
RT   identification.";
RL   Nature 440:497-500(2006).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1-214 (ISOFORM 1).
RA   Igarashi M.;
RL   Submitted (JUN-1994) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 215-646 (ISOFORM 1).
RX   PubMed=1840647; DOI=10.1038/353080a0;
RA   Igarashi M., Nagata A., Jinno S., Suto K., Okayama H.;
RT   "Wee1(+)-like gene in human cells.";
RL   Nature 353:80-83(1991).
RN   [8]
RP   CHARACTERIZATION, AND MUTAGENESIS OF LYS-328.
RX   PubMed=8428596; DOI=10.1002/j.1460-2075.1993.tb05633.x;
RA   McGowan C.H., Russell P.;
RT   "Human Wee1 kinase inhibits cell division by phosphorylating p34cdc2
RT   exclusively on Tyr15.";
RL   EMBO J. 12:75-85(1993).
RN   [9]
RP   PHOSPHORYLATION AT SER-642.
RC   TISSUE=Testis;
RX   PubMed=15150265; DOI=10.1074/jbc.m404728200;
RA   Lu R., Niida H., Nakanishi M.;
RT   "Human SAD1 kinase is involved in UV-induced DNA damage checkpoint
RT   function.";
RL   J. Biol. Chem. 279:31164-31170(2004).
RN   [10]
RP   PHOSPHORYLATION AT SER-53 AND SER-123, UBIQUITINATION, AND MUTAGENESIS OF
RP   SER-53; 116-GLU-GLU-117 AND SER-123.
RX   PubMed=15070733; DOI=10.1073/pnas.0307700101;
RA   Watanabe N., Arai H., Nishihara Y., Taniguchi M., Watanabe N., Hunter T.,
RA   Osada H.;
RT   "M-phase kinases induce phospho-dependent ubiquitination of somatic Wee1 by
RT   SCFbeta-TrCP.";
RL   Proc. Natl. Acad. Sci. U.S.A. 101:4419-4424(2004).
RN   [11]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18220336; DOI=10.1021/pr0705441;
RA   Cantin G.T., Yi W., Lu B., Park S.K., Xu T., Lee J.-D., Yates J.R. III;
RT   "Combining protein-based IMAC, peptide-based IMAC, and MudPIT for efficient
RT   phosphoproteomic analysis.";
RL   J. Proteome Res. 7:1346-1351(2008).
RN   [12]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-85; SER-150; THR-190 AND
RP   SER-312, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of the
RT   kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [13]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-139, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [14]
RP   PHOSPHORYLATION AT SER-642, AND MUTAGENESIS OF SER-642.
RX   PubMed=20026642; DOI=10.1242/jcs.058230;
RA   Muller M., Lutter D., Puschel A.W.;
RT   "Persistence of the cell-cycle checkpoint kinase Wee1 in SadA- and SadB-
RT   deficient neurons disrupts neuronal polarity.";
RL   J. Cell Sci. 123:286-294(2010).
RN   [15]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-127 AND SER-139, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [16]
RP   PHOSPHORYLATION AT THR-239, AND DEPHOSPHORYLATION.
RX   PubMed=22692537; DOI=10.1038/ncomms1886;
RA   Visconti R., Palazzo L., Della Monica R., Grieco D.;
RT   "Fcp1-dependent dephosphorylation is required for M-phase-promoting factor
RT   inactivation at mitosis exit.";
RL   Nat. Commun. 3:894-894(2012).
RN   [17]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-137; SER-139; THR-187;
RP   THR-190; SER-270; SER-307 AND SER-312, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [18]
RP   DEPHOSPHORYLATION AT SER-53 AND SER-123 BY SERINE/THREONINE-PROTEIN
RP   PHOSPHATASE 2A.
RX   PubMed=33108758; DOI=10.1016/j.molcel.2020.10.008;
RA   Li F., Kozono D., Deraska P., Branigan T., Dunn C., Zheng X.F., Parmar K.,
RA   Nguyen H., DeCaprio J., Shapiro G.I., Chowdhury D., D'Andrea A.D.;
RT   "CHK1 Inhibitor Blocks Phosphorylation of FAM122A and Promotes Replication
RT   Stress.";
RL   Mol. Cell 0:0-0(2020).
RN   [19]
RP   X-RAY CRYSTALLOGRAPHY (1.81 ANGSTROMS) OF 291-575 IN COMPLEX WITH MAGNESIUM
RP   AND AN INHIBITOR.
RX   PubMed=15837193; DOI=10.1016/j.str.2004.12.017;
RA   Squire C.J., Dickson J.M., Ivanovic I., Baker E.N.;
RT   "Structure and inhibition of the human cell cycle checkpoint kinase, Wee1A
RT   kinase: an atypical tyrosine kinase with a key role in CDK1 regulation.";
RL   Structure 13:541-550(2005).
RN   [20]
RP   VARIANTS [LARGE SCALE ANALYSIS] CYS-210 AND ILE-472.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G.,
RA   Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S.,
RA   Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G.,
RA   Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K.,
RA   Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D.,
RA   Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R.,
RA   Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A.,
RA   Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F.,
RA   Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F.,
RA   Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G.,
RA   Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R.,
RA   Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Acts as a negative regulator of entry into mitosis (G2 to M
CC       transition) by protecting the nucleus from cytoplasmically activated
CC       cyclin B1-complexed CDK1 before the onset of mitosis by mediating
CC       phosphorylation of CDK1 on 'Tyr-15'. Specifically phosphorylates and
CC       inactivates cyclin B1-complexed CDK1 reaching a maximum during G2 phase
CC       and a minimum as cells enter M phase. Phosphorylation of cyclin B1-CDK1
CC       occurs exclusively on 'Tyr-15' and phosphorylation of monomeric CDK1
CC       does not occur. Its activity increases during S and G2 phases and
CC       decreases at M phase when it is hyperphosphorylated. A correlated
CC       decrease in protein level occurs at M/G1 phase, probably due to its
CC       degradation.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-tyrosyl-[protein] = ADP + H(+) + O-phospho-L-tyrosyl-
CC         [protein]; Xref=Rhea:RHEA:10596, Rhea:RHEA-COMP:10136, Rhea:RHEA-
CC         COMP:10137, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:46858,
CC         ChEBI:CHEBI:82620, ChEBI:CHEBI:456216; EC=2.7.10.2;
CC         Evidence={ECO:0000255|PROSITE-ProRule:PRU10027};
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420;
CC       Note=Binds 2 magnesium ions per subunit.;
CC   -!- ACTIVITY REGULATION: Synthesis is increased during S and G2 phases,
CC       presumably by an increase in transcription; activity is decreased by
CC       phosphorylation during m phase. Protein levels fall in M phase as a
CC       result of decreased synthesis combined with degradation. Activity seems
CC       to be negatively regulated by phosphorylation upon entry into mitosis,
CC       although N-terminal phosphorylation might also regulate the protein
CC       stability via protection from proteolysis or might regulate the
CC       subcellular location.
CC   -!- INTERACTION:
CC       P30291; Q9Y297: BTRC; NbExp=2; IntAct=EBI-914695, EBI-307461;
CC       P30291; Q9UKB1: FBXW11; NbExp=3; IntAct=EBI-914695, EBI-355189;
CC       P30291; P53350: PLK1; NbExp=2; IntAct=EBI-914695, EBI-476768;
CC       P30291; P63104: YWHAZ; NbExp=3; IntAct=EBI-914695, EBI-347088;
CC   -!- SUBCELLULAR LOCATION: Nucleus.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=P30291-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P30291-2; Sequence=VSP_044959;
CC   -!- PTM: Phosphorylated during M and G1 phases. Also autophosphorylated.
CC       Phosphorylation at Ser-642 by BRSK1 and BRSK2 in post-mitotic neurons,
CC       leads to down-regulate WEE1 activity in polarized neurons.
CC       Phosphorylated at Ser-53 and Ser-123 by PLK1 and CDK1, respectively,
CC       generating an signal for degradation that can be recognized by the
CC       SCF(BTRC) complex, leading to its ubiquitination and degradation at the
CC       onset of G2/M phase. {ECO:0000269|PubMed:15070733,
CC       ECO:0000269|PubMed:15150265, ECO:0000269|PubMed:20026642,
CC       ECO:0000269|PubMed:22692537}.
CC   -!- PTM: Dephosphorylated at Thr-239 by CTDP1 (PubMed:22692537).
CC       Dephosphorylated at Ser-53 and Ser-123 by the serine/threonine-protein
CC       phosphatase 2A preventing its ubiquitin-mediated degradation
CC       (PubMed:33108758). {ECO:0000269|PubMed:22692537,
CC       ECO:0000269|PubMed:33108758}.
CC   -!- PTM: Ubiquitinated and degraded at the onset of G2/M phase.
CC       {ECO:0000269|PubMed:15070733}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Ser/Thr protein
CC       kinase family. WEE1 subfamily. {ECO:0000255|PROSITE-ProRule:PRU00159}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; U10564; AAB60401.1; -; mRNA.
DR   EMBL; AJ277546; CAC14173.1; -; Genomic_DNA.
DR   EMBL; AK122837; BAG53753.1; -; mRNA.
DR   EMBL; AC011979; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC122179; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471064; EAW68586.1; -; Genomic_DNA.
DR   EMBL; CH471064; EAW68587.1; -; Genomic_DNA.
DR   EMBL; CH471064; EAW68588.1; -; Genomic_DNA.
DR   EMBL; X62048; CAA43979.1; -; mRNA.
DR   CCDS; CCDS44536.1; -. [P30291-2]
DR   CCDS; CCDS7800.1; -. [P30291-1]
DR   PIR; S55048; S55048.
DR   RefSeq; NP_001137448.1; NM_001143976.1. [P30291-2]
DR   RefSeq; NP_003381.1; NM_003390.3. [P30291-1]
DR   PDB; 1X8B; X-ray; 1.81 A; A=291-575.
DR   PDB; 2IN6; X-ray; 1.90 A; A=291-575.
DR   PDB; 2IO6; X-ray; 2.20 A; A=291-575.
DR   PDB; 2Z2W; X-ray; 2.22 A; A=291-575.
DR   PDB; 3BI6; X-ray; 2.20 A; A=291-575.
DR   PDB; 3BIZ; X-ray; 2.20 A; A=291-575.
DR   PDB; 3CQE; X-ray; 2.50 A; A=291-575.
DR   PDB; 3CR0; X-ray; 2.30 A; A=291-575.
DR   PDB; 5V5Y; X-ray; 1.90 A; A=291-575.
DR   PDB; 5VC3; X-ray; 1.97 A; A=291-575.
DR   PDB; 5VC4; X-ray; 2.10 A; A=291-575.
DR   PDB; 5VC5; X-ray; 1.93 A; A=291-575.
DR   PDB; 5VC6; X-ray; 2.00 A; A=291-575.
DR   PDB; 5VD2; X-ray; 2.05 A; A=291-575.
DR   PDB; 5VD4; X-ray; 2.02 A; A=291-575.
DR   PDB; 5VD5; X-ray; 2.05 A; A=291-575.
DR   PDB; 5VD7; X-ray; 2.08 A; A=291-575.
DR   PDB; 5VD8; X-ray; 1.85 A; A=291-575.
DR   PDB; 5VD9; X-ray; 1.87 A; A=291-575.
DR   PDB; 5VDA; X-ray; 2.10 A; A=291-575.
DR   PDB; 7N3U; X-ray; 2.65 A; A=291-575.
DR   PDBsum; 1X8B; -.
DR   PDBsum; 2IN6; -.
DR   PDBsum; 2IO6; -.
DR   PDBsum; 2Z2W; -.
DR   PDBsum; 3BI6; -.
DR   PDBsum; 3BIZ; -.
DR   PDBsum; 3CQE; -.
DR   PDBsum; 3CR0; -.
DR   PDBsum; 5V5Y; -.
DR   PDBsum; 5VC3; -.
DR   PDBsum; 5VC4; -.
DR   PDBsum; 5VC5; -.
DR   PDBsum; 5VC6; -.
DR   PDBsum; 5VD2; -.
DR   PDBsum; 5VD4; -.
DR   PDBsum; 5VD5; -.
DR   PDBsum; 5VD7; -.
DR   PDBsum; 5VD8; -.
DR   PDBsum; 5VD9; -.
DR   PDBsum; 5VDA; -.
DR   PDBsum; 7N3U; -.
DR   AlphaFoldDB; P30291; -.
DR   SMR; P30291; -.
DR   BioGRID; 113303; 112.
DR   DIP; DIP-37969N; -.
DR   IntAct; P30291; 29.
DR   MINT; P30291; -.
DR   STRING; 9606.ENSP00000402084; -.
DR   BindingDB; P30291; -.
DR   ChEMBL; CHEMBL5491; -.
DR   DrugBank; DB07265; 3-(9-HYDROXY-1,3-DIOXO-4-PHENYL-2,3-DIHYDROPYRROLO[3,4-C]CARBAZOL-6(1H)-YL)PROPANOIC ACID.
DR   DrugBank; DB07257; 4-(2-chlorophenyl)-8-(2-hydroxyethyl)-6-methylpyrrolo[3,4-e]indole-1,3(2H,6H)-dione.
DR   DrugBank; DB08365; 8-bromo-4-(2-chlorophenyl)-N-(2-hydroxyethyl)-6-methyl-1,3-dioxo-1,2,3,6-tetrahydropyrrolo[3,4-e]indole-7-carboxamide.
DR   DrugBank; DB04608; 9-HYDROXY-4-PHENYL-6H-PYRROLO[3,4-C]CARBAZOLE-1,3-DIONE.
DR   DrugBank; DB07006; 9-HYDROXY-6-(3-HYDROXYPROPYL)-4-(2-METHOXYPHENYL)PYRROLO[3,4-C]CARBAZOLE-1,3(2H,6H)-DIONE.
DR   DrugBank; DB12010; Fostamatinib.
DR   DrugBank; DB11740; MK-1775.
DR   DrugBank; DB07226; N-[4-(2-CHLOROPHENYL)-1,3-DIOXO-1,2,3,6-TETRAHYDROPYRROLO[3,4-C]CARBAZOL-9-YL]FORMAMIDE.
DR   DrugCentral; P30291; -.
DR   GuidetoPHARMACOLOGY; 2278; -.
DR   iPTMnet; P30291; -.
DR   PhosphoSitePlus; P30291; -.
DR   BioMuta; WEE1; -.
DR   DMDM; 1351419; -.
DR   EPD; P30291; -.
DR   jPOST; P30291; -.
DR   MassIVE; P30291; -.
DR   MaxQB; P30291; -.
DR   PaxDb; P30291; -.
DR   PeptideAtlas; P30291; -.
DR   PRIDE; P30291; -.
DR   ProteomicsDB; 3755; -.
DR   ProteomicsDB; 54650; -. [P30291-1]
DR   Antibodypedia; 3903; 675 antibodies from 38 providers.
DR   DNASU; 7465; -.
DR   Ensembl; ENST00000299613.10; ENSP00000299613.5; ENSG00000166483.12. [P30291-2]
DR   Ensembl; ENST00000450114.7; ENSP00000402084.2; ENSG00000166483.12. [P30291-1]
DR   Ensembl; ENST00000681684.1; ENSP00000506667.1; ENSG00000166483.12. [P30291-2]
DR   GeneID; 7465; -.
DR   KEGG; hsa:7465; -.
DR   MANE-Select; ENST00000450114.7; ENSP00000402084.2; NM_003390.4; NP_003381.1.
DR   UCSC; uc001mhs.4; human. [P30291-1]
DR   CTD; 7465; -.
DR   DisGeNET; 7465; -.
DR   GeneCards; WEE1; -.
DR   HGNC; HGNC:12761; WEE1.
DR   HPA; ENSG00000166483; Low tissue specificity.
DR   MIM; 193525; gene.
DR   neXtProt; NX_P30291; -.
DR   OpenTargets; ENSG00000166483; -.
DR   PharmGKB; PA366; -.
DR   VEuPathDB; HostDB:ENSG00000166483; -.
DR   eggNOG; KOG0601; Eukaryota.
DR   GeneTree; ENSGT00940000157939; -.
DR   HOGENOM; CLU_000288_25_1_1; -.
DR   InParanoid; P30291; -.
DR   OMA; NSEGKCR; -.
DR   PhylomeDB; P30291; -.
DR   TreeFam; TF101088; -.
DR   BRENDA; 2.7.10.2; 2681.
DR   PathwayCommons; P30291; -.
DR   Reactome; R-HSA-156711; Polo-like kinase mediated events.
DR   Reactome; R-HSA-69202; Cyclin E associated events during G1/S transition.
DR   Reactome; R-HSA-69273; Cyclin A/B1/B2 associated events during G2/M transition.
DR   Reactome; R-HSA-69478; G2/M DNA replication checkpoint.
DR   Reactome; R-HSA-69656; Cyclin A:Cdk2-associated events at S phase entry.
DR   Reactome; R-HSA-75035; Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex.
DR   Reactome; R-HSA-983231; Factors involved in megakaryocyte development and platelet production.
DR   SignaLink; P30291; -.
DR   SIGNOR; P30291; -.
DR   BioGRID-ORCS; 7465; 806 hits in 1124 CRISPR screens.
DR   ChiTaRS; WEE1; human.
DR   EvolutionaryTrace; P30291; -.
DR   GeneWiki; Wee1-like_protein_kinase; -.
DR   GenomeRNAi; 7465; -.
DR   Pharos; P30291; Tchem.
DR   PRO; PR:P30291; -.
DR   Proteomes; UP000005640; Chromosome 11.
DR   RNAct; P30291; protein.
DR   Bgee; ENSG00000166483; Expressed in ventricular zone and 182 other tissues.
DR   ExpressionAtlas; P30291; baseline and differential.
DR   Genevisible; P30291; HS.
DR   GO; GO:0005737; C:cytoplasm; IEA:Ensembl.
DR   GO; GO:0005730; C:nucleolus; IDA:HPA.
DR   GO; GO:0005654; C:nucleoplasm; TAS:Reactome.
DR   GO; GO:0005634; C:nucleus; IBA:GO_Central.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0000287; F:magnesium ion binding; IEA:InterPro.
DR   GO; GO:0004715; F:non-membrane spanning protein tyrosine kinase activity; IEA:UniProtKB-EC.
DR   GO; GO:0004672; F:protein kinase activity; IBA:GO_Central.
DR   GO; GO:0004713; F:protein tyrosine kinase activity; IBA:GO_Central.
DR   GO; GO:0051301; P:cell division; IEA:UniProtKB-KW.
DR   GO; GO:0030010; P:establishment of cell polarity; IEA:Ensembl.
DR   GO; GO:0000086; P:G2/M transition of mitotic cell cycle; TAS:Reactome.
DR   GO; GO:0000226; P:microtubule cytoskeleton organization; IEA:Ensembl.
DR   GO; GO:2000134; P:negative regulation of G1/S transition of mitotic cell cycle; TAS:Reactome.
DR   GO; GO:0048812; P:neuron projection morphogenesis; IEA:Ensembl.
DR   DisProt; DP00611; -.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   InterPro; IPR017164; Wee1-like_protein_kinase.
DR   Pfam; PF00069; Pkinase; 1.
DR   PIRSF; PIRSF037281; Wee1-like_protein_kinase; 1.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; ATP-binding; Cell cycle; Cell division;
KW   Kinase; Magnesium; Metal-binding; Mitosis; Nucleotide-binding; Nucleus;
KW   Phosphoprotein; Reference proteome; Transferase; Tyrosine-protein kinase;
KW   Ubl conjugation.
FT   CHAIN           1..646
FT                   /note="Wee1-like protein kinase"
FT                   /id="PRO_0000086810"
FT   DOMAIN          299..569
FT                   /note="Protein kinase"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   REGION          1..181
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        32..46
FT                   /note="Acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        61..80
FT                   /note="Pro residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        157..181
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   ACT_SITE        426
FT                   /note="Proton acceptor"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159,
FT                   ECO:0000255|PROSITE-ProRule:PRU10027"
FT   BINDING         305..313
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   BINDING         328
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   BINDING         431
FT                   /ligand="Mg(2+)"
FT                   /ligand_id="ChEBI:CHEBI:18420"
FT                   /evidence="ECO:0000269|PubMed:15837193"
FT   BINDING         463
FT                   /ligand="Mg(2+)"
FT                   /ligand_id="ChEBI:CHEBI:18420"
FT                   /evidence="ECO:0000269|PubMed:15837193"
FT   MOD_RES         53
FT                   /note="Phosphoserine; by PLK1"
FT                   /evidence="ECO:0000269|PubMed:15070733"
FT   MOD_RES         78
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q63802"
FT   MOD_RES         85
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18691976"
FT   MOD_RES         123
FT                   /note="Phosphoserine; by CDK1"
FT                   /evidence="ECO:0000269|PubMed:15070733"
FT   MOD_RES         127
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:20068231"
FT   MOD_RES         137
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         139
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:19690332,
FT                   ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:23186163"
FT   MOD_RES         150
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18691976"
FT   MOD_RES         165
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P47810"
FT   MOD_RES         187
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         190
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:18691976,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         239
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000269|PubMed:22692537"
FT   MOD_RES         270
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         307
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         312
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18691976,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         642
FT                   /note="Phosphoserine; by BRSK1 and BRSK2"
FT                   /evidence="ECO:0000269|PubMed:15150265,
FT                   ECO:0000269|PubMed:20026642"
FT   VAR_SEQ         1..214
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_044959"
FT   VARIANT         210
FT                   /note="G -> C (in dbSNP:rs34412975)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041302"
FT   VARIANT         472
FT                   /note="S -> I (in dbSNP:rs56411856)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041303"
FT   MUTAGEN         53
FT                   /note="S->A: Abolishes phosphorylation by PLK1 and CDK1 and
FT                   binding of the SCF(BTRC) complex, leading to stabilization
FT                   of the protein; when associated with A-123."
FT                   /evidence="ECO:0000269|PubMed:15070733"
FT   MUTAGEN         116..117
FT                   /note="EE->AA: Impairs binding of the SCF(BTRC) complex."
FT                   /evidence="ECO:0000269|PubMed:15070733"
FT   MUTAGEN         123
FT                   /note="S->A: Abolishes phosphorylation by PLK1 and CDK1 and
FT                   binding of the SCF(BTRC) complex, leading to stabilization
FT                   of the protein; when associated with A-53."
FT                   /evidence="ECO:0000269|PubMed:15070733"
FT   MUTAGEN         328
FT                   /note="K->R: Abolishes activity."
FT                   /evidence="ECO:0000269|PubMed:8428596"
FT   MUTAGEN         642
FT                   /note="S->A: Abolishes phosphorylation by BRSK1 and BRSK2."
FT                   /evidence="ECO:0000269|PubMed:20026642"
FT   CONFLICT        65
FT                   /note="A -> E (in Ref. 6; CAA43979)"
FT                   /evidence="ECO:0000305"
FT   HELIX           294..298
FT                   /evidence="ECO:0007829|PDB:1X8B"
FT   STRAND          299..308
FT                   /evidence="ECO:0007829|PDB:1X8B"
FT   STRAND          311..318
FT                   /evidence="ECO:0007829|PDB:1X8B"
FT   TURN            319..321
FT                   /evidence="ECO:0007829|PDB:1X8B"
FT   STRAND          324..331
FT                   /evidence="ECO:0007829|PDB:1X8B"
FT   STRAND          335..337
FT                   /evidence="ECO:0007829|PDB:5VD5"
FT   HELIX           338..352
FT                   /evidence="ECO:0007829|PDB:1X8B"
FT   STRAND          362..368
FT                   /evidence="ECO:0007829|PDB:1X8B"
FT   STRAND          371..377
FT                   /evidence="ECO:0007829|PDB:1X8B"
FT   HELIX           384..394
FT                   /evidence="ECO:0007829|PDB:1X8B"
FT   HELIX           400..419
FT                   /evidence="ECO:0007829|PDB:1X8B"
FT   HELIX           429..431
FT                   /evidence="ECO:0007829|PDB:1X8B"
FT   STRAND          432..435
FT                   /evidence="ECO:0007829|PDB:1X8B"
FT   STRAND          458..461
FT                   /evidence="ECO:0007829|PDB:1X8B"
FT   HELIX           464..466
FT                   /evidence="ECO:0007829|PDB:5V5Y"
FT   STRAND          468..472
FT                   /evidence="ECO:0007829|PDB:5VD8"
FT   HELIX           480..482
FT                   /evidence="ECO:0007829|PDB:1X8B"
FT   HELIX           485..488
FT                   /evidence="ECO:0007829|PDB:1X8B"
FT   HELIX           495..510
FT                   /evidence="ECO:0007829|PDB:1X8B"
FT   STRAND          518..520
FT                   /evidence="ECO:0007829|PDB:1X8B"
FT   HELIX           521..527
FT                   /evidence="ECO:0007829|PDB:1X8B"
FT   HELIX           540..549
FT                   /evidence="ECO:0007829|PDB:1X8B"
FT   HELIX           554..556
FT                   /evidence="ECO:0007829|PDB:1X8B"
FT   HELIX           560..564
FT                   /evidence="ECO:0007829|PDB:1X8B"
FT   TURN            567..569
FT                   /evidence="ECO:0007829|PDB:5VD8"
SQ   SEQUENCE   646 AA;  71597 MW;  DB00623D304562A0 CRC64;
     MSFLSRQQPP PPRRAGAACT LRQKLIFSPC SDCEEEEEEE EEEGSGHSTG EDSAFQEPDS
     PLPPARSPTE PGPERRRSPG PAPGSPGELE EDLLLPGACP GADEAGGGAE GDSWEEEGFG
     SSSPVKSPAA PYFLGSSFSP VRCGGPGDAS PRGCGARRAG EGRRSPRPDH PGTPPHKTFR
     KLRLFDTPHT PKSLLSKARG IDSSSVKLRG SSLFMDTEKS GKREFDVRQT PQVNINPFTP
     DSLLLHSSGQ CRRRKRTYWN DSCGEDMEAS DYELEDETRP AKRITITESN MKSRYTTEFH
     ELEKIGSGEF GSVFKCVKRL DGCIYAIKRS KKPLAGSVDE QNALREVYAH AVLGQHSHVV
     RYFSAWAEDD HMLIQNEYCN GGSLADAISE NYRIMSYFKE AELKDLLLQV GRGLRYIHSM
     SLVHMDIKPS NIFISRTSIP NAASEEGDED DWASNKVMFK IGDLGHVTRI SSPQVEEGDS
     RFLANEVLQE NYTHLPKADI FALALTVVCA AGAEPLPRNG DQWHEIRQGR LPRIPQVLSQ
     EFTELLKVMI HPDPERRPSA MALVKHSVLL SASRKSAEQL RIELNAEKFK NSLLQKELKK
     AQMAKAAAEE RALFTDRMAT RSTTQSNRTS RLIGKKMNRS VSLTIY
//
